All In Biotech

Drug Trial Radar · NCT06314373

A Study for HSK39775 in Participants With Solid Tumors

A Phase I/II Study to Assess the Safety, Tolerability, PK/PD, and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

243

Planned (sponsor's estimate)

Start

Mar 7, 2024

Primary completion

Feb 1, 2028

Study completion Sep 1, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • HSK39775 MonotherapyDrug

    HSK39775 will be administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE/SAETime frame: From time of informed consent to 28 days post last dose or start of other anti-cancer therapies
  2. DLTTime frame: From the start of first dose to the end of Cycle1(each cycle is 28 days)
  3. MTD/MADTime frame: From the start of first dose to the end of Cycle1(each cycle is 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fundan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.